<DOC>
	<DOC>NCT01719874</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of TCN-032 given to healthy adult volunteers that have been inoculated with the influenza A virus</brief_summary>
	<brief_title>Influenza Virus Challenge Study to Test Monoclonal Antibody TCN-032 as a Treatment for Influenza</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Age 18 to 45 years, inclusive. In good health with no history of major medical conditions Female subjects must not be pregnant or nursing Have not been vaccinated for influenza virus since 2006 Serosusceptible to the challenge virus Nonsmoker or current smoker willing/able to desist Presence of any significant acute or chronic, uncontrolled medical or psychiatric illness History or evidence of autoimmune disease Any history during adulthood of asthma, history of COPD, pulmonary hypertension, reactive airway disease, any chronic lung condition of any etiology), or any use of a bronchodilator or other asthma medication within adulthood History or clinical evidence of recurrent lower respiratory tract infection Positive human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV) antibody screen Subject is diabetic History of frequent epistaxis (nose bleeds) Any nasal or sinus surgery within 6 months of the screening visit Recent and/or recurrent history of autonomic dysfunction (fainting, palpitations, etc.) Any laboratory test, ECG or spirometry which is abnormal and which is deemed by the Investigator(s) to be clinically significant. Any acute medical condition or significant past medical history of hepatic, renal, cardiovascular, pulmonary, gastrointestinal, haematological, locomotor, immunologic, ophthalmologic, metabolic, endocrine, or other diseases Major surgery within 3 months prior to screening visit Evidence of drug of abuse or positive urine Class A drug or alcohol screen prior to admission Subjects symptomatic with hay fever Subjects with a history of significant adverse reactions/allergies History of allergy or intolerance to oseltamivir or zanamivir. Health care workers (including doctors, nurses, medical students, and allied healthcare professionals) anticipated to have patient contact within 2 weeks of viral challenge.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Influenza</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>